COPENHAGEN, Sept 13 (Reuters) - Danish drugmaker Novo Nordisk said new data showed people with type 2 diabetes experienced improvements in controlling blood sugar levels when using its diabetes drug ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...

LONDON (Reuters) - Novo Nordisk's big new drug hope Victoza has been recommended for limited use on Britain's state-run health service as a treatment for diabetes, the Danish drugmaker said on Monday.

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they'll have to compete with Teva's knockoff versions of its own blockbuster Victoza. Under a new patent ...

Novo Nordisk has posted another healthy set of figures for the first nine months of the year this morning, helped by a good start for its new diabetes drug Victoza. Novo Nordisk has posted another ...

Danish drugmaker Novo Nordisk will be celebrating news that Victoza has been recommended as a treatment for diabetes type 2 for National Health Service patients in England and Wales. Danish drugmaker ...

Do not use Victoza® if you or any of your family members have a history of MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While taking Victoza®, tell your doctor if you get a ...

This week there was news from a small study that showed that Novo Nordisk’s Victoza could serve as a viable treatment for type 1 diabetes, as a supplement to insulin. People with type 1 diabetes can ...

A woman who’s been on a drug similar to Ozempic for nearly a decade is sharing what she’s learned. Danielle Payton, 33, is believed to be one of the longest-serving patients on a GLP-1 injection. The ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.